Clinical Trial Update: Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma. [EARLY_Phase 1]

View source ↗

Summary

Biogenea Pharmaceuticals is conducting an early-phase Phase 1 clinical study to evaluate the safety and potential efficacy of the Tamavaq AI-QMMM personalised v…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Tamavaq

Snippet

Sponsor: Biogenea Pharmaceuticals Ltd. | Conditions: Glioma | EARLY_Phase 1 | Status: RECRUITING